Modern approach to the management and treatment of patients with precancerous conditions and changes in the gastric mucosa

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


The modern views and approaches to the management of patients with precancerous conditions and changes in the gastric mucosa are analyzed. There are no national or international recommendations for the management of this category of patients. Several draft recommendations have been published over the past 10 years, but the most noteworthy are the so-called recommendations for the management of precancerous conditions and stomach lesions (2012 and 2019). Representatives of the European society of gastrointestinal endoscopy, the European group for the study of Helicobacter pylori and the microbiota of the European society of pathologists participated in the development of these recommendations. The recommendations are supported by a number of major studies in accordance with the principles of evidence-based medicine. The problem of oncological diseases of the gastrointestinal tract always remains one of the most significant unsolved problems of world health. Today, the issue of timely diagnosis of precancerous conditions is acute. They include harmless, at first glance, conditions that do not have pronounced symptoms, but bring significant inconvenience to the patient’s life. This is what allows precancerous conditions to progress, to transform from benign to malignant neoplasms. There is only one way to prevent the process of cancer formation: timely detection and treatment of precancerous diseases. This is one of the most important tasks of a General practitioner. The constant search for ways to solve the problem of cancer determines the choice of successful, timely tactics of patient management and its favorable outcome. The presented data can be used in practice by internists and gastroenterologists.

Full Text

Restricted Access

References

  1. Гордиенко, А.В. Современные представления о хроническом атрофическом гастрите как о предопухолевом заболевании желудка / А.В. Гордиенко [и др.] // Новые Санкт-Петербургские врачебные ведомости. - 2011. - № 2. - С. 40-43.
  2. Заплутанов, В.А. Качество жизни пациентов пожилого и старческого возраста с онкологической патологией / В.А. Заплутанов [и др.] // Онкология. Журнал им. А.П. Герцена. - 2016. - № 2. - С. 25-28.
  3. Ивашкин, В.Т. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению язвенной болезни / В.Т. Ивашкин, И.В. Маев, А.А. Шептулин // Росс. журн. гастроэнтерологии, гепатологии, колопроктологии. - 2016. - № 26 (6). - С. 40-54.
  4. Литовкин, А.В. Формы оказания паллиативной помощи лицам старшей возрастной группы с онкологией / А.В. Литовкин [и др.] // Современные проблемы науки и образования. - 2017. - № 4. - С. 58.
  5. Павлович, И.М. Активность и степень хронизации процесса в слизистой оболочке желудка у больных с различными типами хронического гастрита / И.М. Павлович [и др.] // Врач-аспирант. - 2012. - № 4 (53). - С. 475-480.
  6. Павлович, И.М. Диагностическая значимость показателей кислотообразующей и пепсинобразующей функций желудка в выявлении предопухолевого потенциала у больных хроническим атрофическим гастритом / И.М. Павлович [и др.] // Медико-биологические и социально- психологические проблемы безопасности в чрезвычайных ситуациях. - 2012. - № 3. - С. 29-32.
  7. Павлович, И.М. Хронический атрофический гастрит: особенности морфологической структуры и пепсинобразующей функции / И.М. Павлович, В.Ю. Голофеевский, В.П. Калиновский // Вопр. онкол. - 2006. - Т. 52, № 3. - С. 353-356.
  8. Пегашева, И.Л. Предикторы развития рака желудка: предопухолевые изменения (кишечная метаплазия и дисплазия), факторы патогенности Helicobacter pylori / И.Л. Пегашева, И.М. Павлович, А.В. Гордиенко // Вестн. Росс. воен.-мед. акад. - 2017. - № 4 (60). - С. 147-152.
  9. Цуканов, В.В. Новые европейские рекомендации по ведению пациентов с предраковыми изменениями в желудке / В.В. Цуканов [и др.] // Мед. совет. - 2019. - № 3. - С. 44-47.
  10. An, J.K. Marginal turbid band and light blue crest, signs observed in magnifying narrow-band imaging endoscopy, are indicative of gastric intestinal metaplasia / J.K. An [et al.] // BMC Gastroenterol. - 2012. - № 12. - Р. 169.
  11. Correa, P. A human model of gastric carcinogenesis / P. Correa // Cancer Res. - 1988. - № 48 (13). - Р. 3554-3560.
  12. Correa, P. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy // P. Correa [et al.] // J. Natl. Cancer Inst. - 2000. - № 92. - Р. 1881-1888.
  13. Correa, P. Gastric precancerous process in a high risk population: cohort follow-up / P. Correa [et al.] // Cancer Res. - 1990. - № 50. - Р. 4737-4740.
  14. de Vries, A.C. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions / A.C. de Vries [et al.] // Helicobacter. - 2010. - № 15. - Р. 259-264.
  15. de Vries, A.C. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology / A.C. de Vries [et al.]. - 2008. - № 134. - Р. 945-952.
  16. Dinis-Ribeiro, M. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia / M. Dinis-Ribeiro [et al.] // J. Gastroenterol. Hepatol. - 2007. - № 22. - Р. 1594-1604.
  17. Dinis-Ribeiro, M. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) / M. Dinis-Ribeiro [et al.] // Virchows Arch. - 2012. - № 460 (1). - Р. 19-46.
  18. Eriksson, N.K. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy / N.K. Eriksson [et al.] // Endoscopy. - 2005. - № 37. Р. - 532-536.
  19. Hung, K.H. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication / K.H. Hung [et al.] // J. Gastroenterol. Hepatol. - 2010. - № 25. - Р. 48-53.
  20. Kim, G.H. Screening and surveillance for gastric cancer in the United States: is it needed? / G.H. Kim [et al.] // Gastrointest Endosc. - 2016. - № 84 (1). - Р. 18-28.
  21. Lauwers, G.Y. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists / G.Y Lauwers [et al.] // Am. J. Surg. Pathol. - 1999. - № 23. - Р. 511-518.
  22. Leung, W.K. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial / W.K. Leung [et al.] // Clin. Cancer Res. - 2006. - № 12. - Р. 4766-4772.
  23. Liu, H. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs / H. Liu [et al.] // BMC Cancer. - 2019. - № 19 (1). - Р. 129.
  24. Matsuda, T. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan / T. Matsuda, K. Saika // Jpn J Clin Oncol. - 2013. - № 43 (11). - Р. 1157-1158.
  25. Pimentel-Nunes, Р. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019 / Р. Pimentel-Nunes [et al.] // Endoscopy. - 2019. - № 51 (4). - Р. 365-388.
  26. Rugge, M. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia / M. Rugge [et al.] // Hum. Pathol. - 1991. - № 22. - Р. 1002-1008.
  27. Siewert, J.R. Prognostic relevance of systematic lymph node dissection in gastric carcinoma: German gastric Carcinoma Study Group / J.R. Siewert [et al.] // Br. J. Surg. - 1993. - № 80 (8). - Р. 1015-1018.
  28. Wang, Z. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis / Z. Wang [et al.] // Int. J. Epidemiol. - 2018. - № 47 (3). - Р. 966-975.
  29. Yanaoka, K. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion / K. Yanaoka [et al.] // Int. J. Cancer. - 2010. - № 126. - Р. 1467-1473.
  30. Yang, H.B. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication / H.B. Yang [et al.] // Aliment. Pharmacol. Ther. - 2009. - № 25. - Р. 455-461.
  31. You, W.C. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer / W.C. You [et al.] // Int. J. Cancer. - 1999. - № 83. - Р. 615-619.
  32. Zhang, L.J. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions / L.J. Zhang [et al.] // World J. Gastroenterol. - 2009. - № 15. - Р. 2731-2738.

Statistics

Views

Abstract - 16

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Pavlovich I.M., Pugacheva I.L., Alper G.A., Yudin V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies